Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fexuprazan PK/PD and Safety Study in Healthy Males
NCT03487562Phase 1Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Apr 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fexuprazan in Helicobacter pylori infection (7 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum concentration at steady state at 48 hours, Minimum concentration at steady state at 48 hours and 11 more. Started Apr 2018; status: completed.
02
Drugs
fexuprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT03487562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03487562.